We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

390 hedge funds and large institutions have $8.26B invested in Cytokinetics in 2024 Q1 according to their latest regulatory filings, with 105 funds opening new positions, 128 increasing their positions, 120 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 61

12% more funds holding

Funds holding: 347 → 390 (+43)

10% more funds holding in top 10

Funds holding in top 10: 20 → 22 (+2)

7% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 120

5% more call options, than puts

Call options by funds: $507M | Put options by funds: $485M

4.67% less ownership

Funds ownership: 119.02% → 114.35% (-4.7%)

15% less capital invested

Capital invested by funds: $9.74B → $8.26B (-$1.49B)

Holders
390
Holders Change
+43
Holders Change %
+12.39%
% of All Funds
5.62%
Holding in Top 10
22
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+10%
% of All Funds
0.32%
New
105
Increased
128
Reduced
120
Closed
61
Calls
$507M
Puts
$485M
Net Calls
+$22.9M
Net Calls Change
-$588M

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$349M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$224M
3
VPC
Vestal Point Capital
New York
+$162M
4
Marshall Wace
Marshall Wace
United Kingdom
+$149M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$127M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$298M
2
BlackRock
BlackRock
New York
-$285M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$194M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$163M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$137M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$870M -$285M -3,687,297 -23%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$764M -$163M -2,106,640 -16%
Vanguard Group
3
Vanguard Group
Pennsylvania
$701M -$78.9M -1,019,813 -9%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$359M +$224M +2,892,104 +130%
Bank of America
5
Bank of America
North Carolina
$335M +$349M +4,510,857 +1,691%
State Street
6
State Street
Massachusetts
$317M -$106M -1,373,000 -23%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$279M -$194M -2,507,040 -39%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$205M -$24.2M -313,302 -10%
Marshall Wace
9
Marshall Wace
United Kingdom
$179M +$149M +1,930,716 +308%
RI
10
RTW Investments
New York
$177M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$158M +$12.1M +157,040 +8%
VPC
12
Vestal Point Capital
New York
$151M +$162M +2,100,000 +4,200%
BC
13
Boxer Capital
California
$147M – – –
AllianceBernstein
14
AllianceBernstein
Tennessee
$124M +$127M +1,647,818 +1,348%
PHS
15
PFM Health Sciences
California
$123M – – –
Pictet Asset Management
16
Pictet Asset Management
Switzerland
$123M +$29.5M +381,402 +28%
PCH
17
Polar Capital Holdings
United Kingdom
$113M +$14.6M +188,522 +13%
AC
18
Armistice Capital
New York
$107M +$118M +1,525,688 New
Invesco
19
Invesco
Georgia
$92.4M +$5.77M +74,558 +6%
Northern Trust
20
Northern Trust
Illinois
$77.9M +$4.29M +55,463 +5%
PCM
21
Pentwater Capital Management
Florida
$75.7M +$83.5M +1,080,000 New
MAM
22
Melqart Asset Management
United Kingdom
$68.9M +$76.1M +983,395 New
Norges Bank
23
Norges Bank
Norway
$68.9M +$20.2M +260,532 +36%
Morgan Stanley
24
Morgan Stanley
New York
$66.9M -$298M -3,848,306 -80%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$63.1M -$22.1M -285,782 -24%
1
2 3 4 5

CYTK Hedge Fund Activity: Q1 2024 in Review

390 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2024, worth a combined $8.26B — down 15% from $9.74B a quarter earlier.

Buyers outnumbered sellers: 105 funds opened new CYTK positions and 61 closed out — a net gain of 44 holders — while 128 added to existing stakes and 120 trimmed.

The largest buyer was Bank of America, adding an estimated $349M. The largest seller was Morgan Stanley, cutting an estimated $298M.

  • 390 institutional investors held Cytokinetics (CYTK) as of Q1 2024, up from 347 in Q4 2023.
  • Funds reported $8.26B of Cytokinetics stock for Q1 2024, down 15% quarter-over-quarter.
  • 105 funds opened new Cytokinetics positions in Q1 2024 and 61 closed out, a net change of +44 holders.
  • The largest Cytokinetics buyer in Q1 2024 was Bank of America, an estimated $349M added.
  • The largest Cytokinetics seller in Q1 2024 was Morgan Stanley, an estimated $298M sold.

Based on aggregated 13F filings for Q1 2024.